Drug toxicity evaluation is an essential process of drug development as it is reportedly
responsible for the attrition of approximately 30% of drug candidates. The rapid increase in …

Abstract The Open Targets Platform (https://www. targetvalidation. org/) provides users with
a queryable knowledgebase and user interface to aid systematic target identification and …

Current gaps in drug safety sciences can result from the inability (1) to identify hazard across
multiple target organs,(2) to predict and risk assess with certainty against drug safety …

Next generation risk assessment (NGRA) is an exposure-led, hypothesis-driven approach
that has the potential to support animal-free safety decision-making. However, significant …

Schistosome parasites kill 250,000 people every year. Treatment of schistosomiasis relies
on the drug praziquantel. Unfortunately, a scarcity of molecular tools has hindered the …

Various sources of information can be used to better understand and predict compound
activity and safety-related endpoints, including biological data such as gene expression and …

Abstract Background Adverse drug reactions (ADRs) are one of the leading causes of
morbidity and mortality in health care. Understanding which drug targets are linked to ADRs …

Most small molecule drugs interact with unintended, often unknown, biological targets and
these off-target interactions may lead to both preclinical and clinical toxic events. Undesired …

The content of this article derives from a Health and Environmental Sciences Institute (HESI)
consortium with a focus to improve cardiac safety during drug development. A detailed …

Within drug development, high off-target promiscuity as well as potent cytotoxicity, are
associated with a high attrition rate. We investigated the safety profile of novel plasmepsin X …